Literature DB >> 15072608

A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer.

Tanyifor M Tohnya1, Sylvia S W Ng, William L Dahut, John J Wright, Philip M Arlen, James L Gulley, Catherine Parker, Jerome Zeldis, William D Figg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15072608     DOI： 10.3816/cgc.2004.n.006

Source DB:  PubMed          Journal:  Clin Prostate Cancer        ISSN： 1540-0352


× No keyword cloud information.
  8 in total

Review 1.  The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective.

Authors:  Jonathan L Finlay; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

Review 2.  New frontiers in the treatment of multiple myeloma.

Authors:  Janice Jin Hwang; Irene M Ghobrial; Kenneth C Anderson
Journal:  ScientificWorldJournal       Date:  2006-12-06

Review 3.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Paul G Kluetz; William D Figg; William L Dahut
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

Review 4.  VEGF inhibitors and prostate cancer therapy.

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

Review 5.  Thalidomide analogues as anticancer drugs.

Authors:  Jeanny B Aragon-Ching; Haiqing Li; Erin R Gardner; William D Figg
Journal:  Recent Pat Anticancer Drug Discov       Date:  2007-06       Impact factor: 4.169

Review 6.  Trial Watch: Lenalidomide-based immunochemotherapy.

Authors:  Michaela Semeraro; Erika Vacchelli; Alexander Eggermont; Jerome Galon; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-10-21       Impact factor: 8.110

Review 7.  Anti-angiogenesis in prostate cancer: knocked down but not out.

Authors:  Marijo Bilusic; Yu-Ning Wong
Journal:  Asian J Androl       Date:  2014 May-Jun       Impact factor: 3.285

8.  Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cells.

Authors:  Karam Kim; Sungkwan An; Hwa Jun Cha; Yeong Min Choi; Sung Jin Choi; In-Sook An; Hong Ghi Lee; Yoo Hong Min; Su-Jae Lee; Seunghee Bae
Journal:  Oncol Lett       Date:  2012-11-30       Impact factor: 2.967
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.